Maven Securities LTD Blueprint Medicines Corp Transaction History

Maven Securities LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $453,549 - $541,400	-5,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $460,400 - $622,400	5,000 New	5,000 $575,000
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $481,100 - $822,200	-10,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $667,300 - $825,900	10,000 New	10,000 $809,000
Q2 2019 Aug 13, 2019	SELL	$73.54 - $97.8 $2.26 Million - $3 Million	-30,700 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $1.5 Million - $2.66 Million	30,700 New	30,700 $2.47 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $366,400 - $514,750	-5,000 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$62.91 - $88.32 $314,550 - $441,599	5,000	5,000 $388,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.38B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.